What You Should Know:
- LG Electronics launches its latest addition to its diagnostic monitor lineup, the 21HQ613D-B. This 21.3-inch 5-megapixel (MP) IPS monitor has received FDA clearance for digital mammography and breast tomosynthesis.
- The new 5MP monitor is designed to improve workflow efficiency by providing healthcare professionals with the tools they need to accurately and comfortably review medical images.
Enhanced Image Quality and User Experience
The
Read More
Breast Cancer
Mika Health, AstraZeneca, and Daiichi Sankyo Partner on UNITE Program
What You Should Know:
- Mika Health, a leading developer of digital therapeutics for cancer patients, announced a collaborative initiative called "UNITE" alongside pharmaceutical giants AstraZeneca and Daiichi Sankyo.
- The strategic initiative signifies a commitment to cross-industry collaboration to enhance the lives of cancer patients and is expected to pave the way for AI-powered solutions in other disease areas.
Mika Health: A Proven Digital Therapeutic Platform
Mika
Read More
New AI Test Aims to Improve Breast Cancer Recurrence Prediction: COTA, PreciseDx, and Baptist Health South Florida Collaborate
What You Should Know:
- A collaborative effort between COTA, PreciseDx, and Baptist Health South Florida seeks to revolutionize breast cancer recurrence risk assessment with the PreciseBreast™ (PDxBr) test. This AI-powered tool holds promise for faster, more accurate, and more affordable risk prediction compared to current methods.
- By utilizing AI technology, PreciseBreast™ has the potential to offer patients a faster, more accurate, and more affordable way to assess their risk of
Read More
UCLA, PreciseDx to Develop AI-Powered Breast Cancer Recurrence Tool for Early Detection
What You Should Know:
- PreciseDx®, a leader in AI-powered diagnostics for oncology, announces a crucial collaboration with UCLA's Department of Pathology and Laboratory Medicine.
- The research initiative focuses on evaluating PreciseDx's innovative tool, PreciseBreast™, for its ability to accurately assess the risk of recurrence in patients diagnosed with triple-negative breast cancer (TNBC).
Why Focus on Triple-Negative Breast Cancer?
TNBC Challenges: Accounting for
Read More
Lunit Acquires AI-Enabled Breast Cancer Detection Platform Volpara for $193M
What You Should Know:
- South Korean AI leader Lunit has announced its intention to acquire Volpara, a global pioneer in AI-powered cancer detection software, in a landmark deal worth AUD 292M (USD 193M).
- Beyond market presence, it's Volpara's deep knowledge and extensive data that truly sets it apart. With over 100 million high-quality mammogram images in its repository, Volpara offers a treasure trove of insights that will supercharge Lunit's AI capabilities and pave the way for
Read More
RSNA23: iCAD, GE HealthCare Integrate to Advance Breast Cancer Detection with AI
What You Should Know:
- iCAD, Inc. (NASDAQ: ICAD), a provider of medical technology and innovative cancer-detection solutions, announced that its ProFound Breast Health Suite will be integrated into GE HealthCare’s new MyBreastAI Suite offering.
- This integration coincides with GE HealthCare’s and iCAD’s presence at the Radiological Society of North America (RSNA) annual meeting in Chicago as it unveils new research evaluating its ProFound AI in breast cancer risk detection and heart
Read More
Why AI Can Potentially Revolutionize Breast Cancer Detection
Breast cancer awareness is essential for early detection, which is critical for improving survival rates and reducing the burden of this disease. October is Breast Cancer Awareness Month, but education and awareness should not be limited to just one month of the year. A large portion of the global population will experience or be impacted by breast cancer; one in eight women will face a diagnosis in their lives, and this affects both them and their families.
Exciting advancements in the realm
Read More
Intelerad, Densitas Partner on AI-Powered Breast Cancer Screenings
What You Should Know:
- Densitas®, a provider of artificial intelligence solutions for breast cancer screening, announced a strategic partnership with Intelerad Medical Systems®, a provider of medical imaging software and services to advance AI-driven breast cancer screening.
- This partnership strengthens clinical decision-making, increases operational efficiencies, reduces costs, and improves mammography quality and mammography facility adherence with MQSA EQUIP
Read More
Ibex Launches Breast Cancer Biomarker Diagnostic Platform
What You Should Know:
Ibex Medical Analytics launches Galen Breast HER2™, a novel breast cancer AI-powered biomarker scoring solution developed in collaboration with AstraZeneca and Daiichi Sankyo, to support improved patient outcomes.Galen Breast HER2 is an AI-powered biomarker scoring solution to aid pathologists with reproductible HER2 assessment for breast cancer. The platform allows clinicians to rapidly and accurately identify patients with HER2-low who would benefit from
Read More
Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care
What You Should Know:
- A recent study published in JAMA found that conventional genomic tests commonly used for breast cancer tumors can be less accurate for Black women. This news comes at a time when Black women with breast cancer are experiencing mortality rates that are 41% higher than white women.
- Dr. Nathalie Johnson, MD FACS and President of The American Society of Breast Cancer Surgeons is among numerous doctors who advocate for Agendia and its tests which look beyond race,
Read More
